Stock Research for ADXS

ADXS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ADXS Stock Chart & Research Data

The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADXS Due diligence Resources & Stock Charts

The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADXS Detailed Price Forecast - CNN Money CNN View ADXS Detailed Summary - Google Finance
Yahoo View ADXS Detailed Summary - Yahoo! Finance Zacks View ADXS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ADXS Trends & Analysis - Trade-Ideas Barrons View ADXS Major Holders - Barrons
NASDAQ View ADXS Call Transcripts - NASDAQ Seeking View ADXS Breaking News & Analysis - Seeking Alpha
Spotlight View ADXS Annual Report - CompanySpotlight.com OTC Report View ADXS OTC Short Report - OTCShortReport.com
TradeKing View ADXS Fundamentals - TradeKing Charts View ADXS SEC Filings - Bar Chart
WSJ View Historical Prices for ADXS - The WSJ Morningstar View Performance/Total Return for ADXS - Morningstar
MarketWatch View the Analyst Estimates for ADXS - MarketWatch CNBC View the Earnings History for ADXS - CNBC
StockMarketWatch View the ADXS Earnings - StockMarketWatch MacroAxis View ADXS Buy or Sell Recommendations - MacroAxis
Bullish View the ADXS Bullish Patterns - American Bulls Short Pains View ADXS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ADXS Stock Mentions - StockTwits PennyStocks View ADXS Stock Mentions - PennyStockTweets
Twitter View ADXS Stock Mentions - Twitter Invest Hub View ADXS Investment Forum News - Investor Hub
Yahoo View ADXS Stock Mentions - Yahoo! Message Board Seeking Alpha View ADXS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ADXS - SECform4.com Insider Cow View Insider Transactions for ADXS - Insider Cow
CNBC View ADXS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADXS - OTC Markets
Yahoo View Insider Transactions for ADXS - Yahoo! Finance NASDAQ View Institutional Holdings for ADXS - NASDAQ


Stock Charts

FinViz View ADXS Stock Insight & Charts - FinViz.com StockCharts View ADXS Investment Charts - StockCharts.com
BarChart View ADXS Stock Overview & Charts - BarChart Trading View View ADXS User Generated Charts - Trading View




Latest Financial News for ADXS


Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting
Posted on Tuesday November 06, 2018

Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC). The poster, entitled “Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy,” evaluated the impact of Lm-based immunotherapy on the activation of NK cells in a murine model of human papillomavirus (HPV)-associated tumors.


Advaxis Provides Update on Clinical Pipeline
Posted on Friday November 02, 2018

Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV). The current trial design has a planned sample size of 450 subjects to maintain adequate statistical power over a broader range of survival outcomes, as well as a pre-planned interim analysis (IA) of safety and efficacy. The Company anticipates that over the next couple of months it will finalize the redesign of the trial and review it with the U.S. Food and Drug Administration (FDA).


Advaxis to Host Business Update Conference Call on November 2, 2018
Posted on Friday October 26, 2018

Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.


Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence
Posted on Thursday October 18, 2018

NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.